Suppr超能文献

从多组分组合文库中发现依赖于 CRBN 的 WEE1 分子胶降解剂。

Discovery of CRBN-Dependent WEE1 Molecular Glue Degraders from a Multicomponent Combinatorial Library.

机构信息

Department of Chemistry, Stanford School of Humanities and Sciences, Stanford University, Stanford, California 94305, United States.

Department of Chemical and Systems Biology, ChEM-H, Stanford School of Medicine, Stanford University, Stanford, California 94305, United States.

出版信息

J Am Chem Soc. 2024 Nov 20;146(46):31433-31443. doi: 10.1021/jacs.4c06127. Epub 2024 Nov 5.

Abstract

Small molecules promoting protein-protein interactions produce a range of therapeutic outcomes. Molecular glue degraders exemplify this concept due to their compact drug-like structures and ability to engage targets without reliance on existing cognate ligands. While cereblon molecular glue degraders containing glutarimide scaffolds have been approved for treatment of multiple myeloma and acute myeloid leukemia, the design of new therapeutically relevant monovalent degraders remains challenging. We report here an approach to glutarimide-containing molecular glue synthesis using multicomponent reactions as a central modular core-forming step. Screening the resulting library identified HRZ-1 derivatives that target casein kinase 1 α (CK1α) and Wee-like protein kinase (WEE1). Further medicinal chemistry efforts led to identification of selective monovalent WEE1 degraders that provide a potential starting point for the eventual development of a selective chemical degrader probe. The structure of the hit WEE1 degrader complex with CRBN-DDB1 and WEE1 provides a model of the protein-protein interface and ideas to rationalize the observed kinase selectivity. Our findings suggest that modular synthetic routes combined with in-depth structural characterization give access to selective molecular glue degraders and expansion of the CRBN-degradable proteome.

摘要

小分子促进蛋白质-蛋白质相互作用产生了一系列治疗效果。分子胶降解剂就是这种概念的典范,因为它们具有紧凑的类似药物的结构,并且能够在不依赖现有同源配体的情况下与靶标结合。虽然含有戊二酰亚胺支架的cereblon 分子胶降解剂已被批准用于治疗多发性骨髓瘤和急性髓细胞性白血病,但设计新的治疗相关单价降解剂仍然具有挑战性。我们在这里报告了一种使用多组分反应作为核心形成步骤的含戊二酰亚胺分子胶合成方法。对所得文库进行筛选,鉴定出靶向酪蛋白激酶 1α(CK1α)和 WEE 样蛋白激酶(WEE1)的 HRZ-1 衍生物。进一步的药物化学努力导致了选择性单价 WEE1 降解剂的鉴定,为最终开发选择性化学降解剂探针提供了潜在的起点。与 CRBN-DDB1 和 WEE1 结合的命中 WEE1 降解剂复合物的结构提供了蛋白质-蛋白质界面的模型,并为观察到的激酶选择性提供了合理化的思路。我们的研究结果表明,模块化合成路线与深入的结构表征相结合,可以获得选择性分子胶降解剂,并扩展 CRBN 可降解蛋白质组。

相似文献

本文引用的文献

1
Targeted protein degradation via intramolecular bivalent glues.通过分子内双价胶实现靶向蛋白降解。
Nature. 2024 Mar;627(8002):204-211. doi: 10.1038/s41586-024-07089-6. Epub 2024 Feb 21.
4
From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation.从沙利度胺到针对靶向蛋白降解的合理分子胶设计。
Annu Rev Pharmacol Toxicol. 2024 Jan 23;64:291-312. doi: 10.1146/annurev-pharmtox-022123-104147. Epub 2023 Aug 16.
6
Accelerating Drug Discovery: Synthesis of Complex Chemotypes via Multicomponent Reactions.加速药物发现:通过多组分反应合成复杂化学型
ACS Med Chem Lett. 2023 Mar 8;14(4):376-385. doi: 10.1021/acsmedchemlett.3c00012. eCollection 2023 Apr 13.
8
Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells.双 IKZF2 和 CK1α 降解剂靶向急性髓系白血病细胞。
Cancer Cell. 2023 Apr 10;41(4):726-739.e11. doi: 10.1016/j.ccell.2023.02.010. Epub 2023 Mar 9.
10
Design, synthesis, and biological evaluation of Wee1 kinase degraders.设计、合成及 Wee1 激酶降解剂的生物学评估。
Eur J Med Chem. 2022 Dec 5;243:114786. doi: 10.1016/j.ejmech.2022.114786. Epub 2022 Sep 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验